Alicia Morgans: Hi, this is Alicia Morgans, GU medical oncologist, and Associate Professor of Medicine at Northwestern University in Chicago. I am so excited to have here with me today, a friend and colleague, Dr. Ashish Kamat, who is a tenured professor of Urology at the MD Anderson Cancer Center in Houston, Texas. Thank you so […]
{{header-clinical-trials-navigation}} A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency Condition: Hormone-Sensitive Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04493853 Sponsor: AstraZeneca Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum […]
Molecular diagnostics can be decisive in the differential diagnosis between a somatic metastasis of type II testicular germ cell tumor (TGCT) or a second primary carcinoma. This is in line with recent recommendations from the International Society of Urological Pathology, based on an international survey which showed that molecular testing is currently only performed by […]
To provide a review of high-risk urologic cancers and the feasibility of delaying surgery without impacting oncologic or mortality outcomes. A thorough literature review was performed using PubMed and Google Scholar to identify articles pertaining to surgical delay and genitourinary oncology.
Papillary renal cell carcinoma (pRCC) was the 2nd most common subtype, accounting for approximately 15% incidence of renal cell carcinoma (RCC). Immune related long non-coding RNAs (IR-lncRs) plentiful in immune cells and immune microenvironment (IME) are potential in evaluating prognosis and assessing the effects of immunotherapy.
The neutrophil-lymphocyte ratio (NLR) is a well-known prognostic marker in various cancers. However, its role as a predictive marker for the effectiveness of nivolumab in patients with metastatic RCC (mRCC) remains unclear.
To identify baseline imaging and clinical characteristics of patients that may improve risk stratification among patients being evaluated for active surveillance (AS). From July 2007 to January 2020, patients referred to our institution for prostate cancer were evaluated and those that remained on AS were identified.
The Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) categorizes the likelihood of clinically significant prostate cancer (csPCa) on magnetic resonance imaging (MRI) and determines the diagnostic pathway.
To characterize Bacillus Calmette-Guérin (BCG) treatment patterns and associated outcomes in a large cohort of patients with non-muscle-invasive bladder cancer (NMIBC). Our retrospective analysis of patients aged ≥ 66 years with stage 0-1 urothelial bladder carcinoma diagnosed between 2000 and 2012 in the US Surveillance, Epidemiology, and End Results (SEER)-Medicare database estimated proxies for recurrence […]
Treatment for muscle-invasive bladder cancer (MIBC) includes radical cystectomy (RC), a major surgery that can be associated with significant toxicity. Limited data exist related to changes in patients’ global health status and recovery following RC.
